HK Stock MarketDetailed Quotes

DUALITYBIO-B (09606)

Watchlist
  • 195.700
  • +6.200+3.27%
15min DelayNot Open Aug 25 16:07 CST
17.77BMarket Cap-6.19P/E (TTM)

DUALITYBIO-B (09606) Income Statement

Cumulative·All
YOY yoy
Hide blank lines yoy
Currency: CNY
2025/FY
2025/H1
2024/FY
2024/Q9
2024/Q1
2023/FY
2023/Q9
2023/Q1
2022/FY
Total Revenue
-4.61%1.85B
--1.23B
+8.66%1.94B
-12.76%1.46B
+2421.85%640.90M
+111558.75%1.79B
--1.68B
--25.41M
--1.60M
Operating Revenue
-4.61%1.85B
--1.23B
+8.66%1.94B
-12.76%1.46B
+2421.85%640.90M
+111558.75%1.79B
--1.68B
--25.41M
--1.60M
Cost of Revenue
-9.17%-1.26B
---639.53M
-170.45%-1.16B
-147.55%-802.46M
-1718.72%-179.34M
---427.66M
---324.16M
---9.86M
----
Cost of Goods Sold
-9.17%-1.26B
---639.53M
-170.45%-1.16B
-147.55%-802.46M
-1718.72%-179.34M
---427.66M
---324.16M
---9.86M
----
Gross Profit
-24.92%589.09M
--589.40M
-42.26%784.67M
-51.21%659.55M
+2867.65%461.56M
+84830.31%1.36B
--1.35B
--15.55M
--1.60M
Operating Expense
-5.72%-1.05B
---474.94M
-60.15%-995.42M
-75.10%-728.77M
-172.25%-366.29M
-67.17%-621.56M
---416.19M
---134.54M
---371.81M
Administrative Expenses
-35.23%-214.61M
---125.55M
-153.64%-158.69M
-189.58%-126.84M
-197.49%-55.20M
-96.01%-62.57M
---43.80M
---18.55M
---31.92M
Research and Development Expenses
-0.12%-837.77M
---349.39M
-49.68%-836.73M
-61.64%-601.93M
-168.21%-311.09M
-64.46%-559.00M
---372.39M
---115.99M
---339.89M
Special Items of Operating Income
-208.39%-23.59M
---7.44M
-50.59%21.76M
-109.62%-3.95M
-40.27%976.00K
+2604.79%44.03M
--41.06M
--1.63M
--1.63M
Operating Profit
-157.61%-486.87M
--107.03M
-124.19%-188.99M
-107.49%-73.17M
+182.01%96.24M
+311.99%781.36M
--976.62M
---117.36M
---368.58M
Financing Income
+106.41%99.31M
--39.47M
+39.52%48.11M
+60.63%38.81M
+480.16%13.33M
+955.17%34.48M
--24.16M
--2.30M
--3.27M
Financing Cost
-384.00%-1.21M
---573.00K
-32.98%-250.00K
-30.34%-189.00K
-22.22%-66.00K
-150.67%-188.00K
---145.00K
---54.00K
---75.00K
Pretax Profit
-155.76%-2.59B
---2.07B
-401.63%-1.01B
-1393.32%-535.90M
+94.01%-47.46M
+47.75%-202.25M
--41.44M
---792.66M
---387.09M
Special Items of Pretax Income
-152.58%-2.21B
---2.22B
+14.19%-873.42M
+47.73%-501.35M
+76.83%-156.97M
-4590.78%-1.02B
---959.20M
---677.55M
---21.70M
Tax
----
----
+76.89%-35.89M
+80.30%-30.58M
---18.48M
---155.26M
---155.26M
----
----
Net Profit
-147.02%-2.59B
---2.07B
-193.82%-1.05B
-397.67%-566.48M
+91.68%-65.94M
+7.64%-357.51M
---113.83M
---792.66M
---387.09M
Profit from Continuing Operations
-147.02%-2.59B
---2.07B
-193.82%-1.05B
-397.67%-566.48M
+91.68%-65.94M
+7.64%-357.51M
---113.83M
---792.66M
---387.09M
Net Income to Parent Company
-147.02%-2.59B
---2.07B
-193.82%-1.05B
-397.67%-566.48M
+91.68%-65.94M
+7.64%-357.51M
---113.83M
---792.66M
---387.09M
Net Income to Common Stockholders
-147.02%-2.59B
---2.07B
-193.82%-1.05B
-397.67%-566.48M
+91.68%-65.94M
+7.64%-357.51M
---113.83M
---792.66M
---387.09M
Basic EPS
+69.69%-39.80
---49.70
-193.74%-131.30
-398.59%-70.80
+91.73%-8.20
+7.64%-44.70
---14.20
---99.10
---48.40
Diluted EPS
+69.69%-39.80
---49.70
-193.74%-131.30
-398.59%-70.80
+91.73%-8.20
+7.64%-44.70
---14.20
---99.10
---48.40
Deadline
Dec 31, 2025
Jun 30, 2025
Dec 31, 2024
Sep 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Mar 31, 2023
Dec 31, 2022
Accounting Standard
HKAS
HKAS
HKAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
--
--
--
--
--
--
--
--
--
2025/FY2025/H12024/FY2024/Q92024/Q12023/FY2023/Q92023/Q12022/FY

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More